Novartis AG PE Ratio 2006-2019 | NVS

Current and historical p/e ratio for Novartis AG (NVS) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novartis AG PE ratio as of February 18, 2020 is 18.63.
Novartis AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2020-02-18 97.20 19.25
2019-12-31 94.69 $5.05 18.75
2019-09-30 86.90 $5.07 17.14
2019-06-30 91.31 $4.87 18.75
2019-03-31 96.14 $5.27 18.24
2018-12-31 85.81 $5.37 15.98
2018-09-30 86.16 $5.70 15.12
2018-06-30 75.54 $5.89 12.83
2018-03-31 80.85 $3.41 23.71
2017-12-31 81.04 $3.25 24.94
2017-09-30 82.87 $2.81 29.49
2017-06-30 80.57 $2.74 29.40
2017-03-31 71.69 $2.66 26.95
2016-12-31 67.87 $2.80 24.24
2016-09-30 73.57 $2.84 25.91
2016-06-30 76.88 $2.80 27.46
2016-03-31 67.50 $2.80 24.11
2015-12-31 77.20 $7.28 10.60
2015-09-30 82.47 $7.45 11.07
2015-06-30 88.23 $7.99 11.04
2015-03-31 88.48 $8.27 10.70
2014-12-31 80.86 $4.14 19.53
2014-09-30 82.14 $4.35 18.88
2014-06-30 79.00 $3.94 20.05
2014-03-31 74.19 $3.94 18.83
2013-12-31 67.88 $3.72 18.25
2013-09-30 64.78 $3.73 17.37
2013-06-30 59.71 $3.84 15.55
2013-03-31 60.16 $3.92 15.35
2012-12-31 51.50 $3.90 13.21
2012-09-30 49.84 $3.55 14.04
2012-06-30 45.48 $3.55 12.81
2012-03-31 45.08 $3.55 12.70
2011-12-31 44.52 $3.80 11.72
2011-09-30 43.43 $4.26 10.20
2011-06-30 47.59 $4.24 11.22
2011-03-31 42.33 $4.19 10.10
2010-12-31 44.02 $4.28 10.29
2010-09-30 43.07 $4.35 9.90
2010-06-30 36.08 $4.28 8.43
2010-03-31 40.40 $4.11 9.83
2009-12-31 39.21 $3.69 10.63
2009-09-30 36.29 $3.34 10.87
2009-06-30 29.38 $3.34 8.80
2009-03-31 27.25 $3.44 7.92
2008-12-31 34.33 $3.59 9.56
2008-09-30 36.45 $3.34 10.91
2008-06-30 37.97 $5.39 7.04
2008-03-31 35.34 $5.26 6.72
2007-12-31 36.40 $5.16 7.05
2007-09-30 36.83 $5.45 6.76
2007-06-30 37.58 $3.28 11.46
2007-03-31 36.61 $3.15 11.62
2006-12-31 37.78 $3.06 12.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $223.748B $47.498B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $395.123B 17.30
Roche Holding AG (RHHBY) Switzerland $297.156B 0.00
Merck (MRK) United States $210.426B 15.93
Pfizer (PFE) United States $202.051B 12.38
Novo Nordisk (NVO) Denmark $150.250B 25.79
AbbVie (ABBV) United States $139.083B 10.52
Eli Lilly (LLY) United States $135.494B 23.36
AstraZeneca (AZN) United Kingdom $125.547B 27.03
Sanofi (SNY) France $125.032B 14.86
GlaxoSmithKline (GSK) United Kingdom $109.143B 13.84
Bristol-Myers Squibb (BMY) United States $108.152B 14.21
Bayer (BAYRY) Germany $78.409B 11.61
H Lundbeck (HLUYY) Denmark $7.617B 13.23